Overview

A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs

Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
To compare the PK profiles of HLX01 and Rituximab in Chinese patients with moderate to severe rheumatoid arthritis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shanghai Henlius Biotech
Treatments:
Rituximab